H7N2 HA Subtype HA Specific Neutra™ Antibody Products

Are you facing challenges in developing broad-spectrum influenza therapeutics or preparing for potential H7N9 pandemic threats? Creative Biolabs' IAV H7 Subtype HA Specific Neutra™ Antibody Products empower your research with high-precision, validation-ready neutralizing antibodies, engineered through advanced hybridoma and phage display platforms to deliver reliable tools for critical virology and vaccine development.

Introduction to Influenza A Virus H7N2 Hemagglutinin (H7N2 HA)

H7N2 is the primary determinant of viral infectivity and a major target for neutralizing antibodies. As a key mediator of host cell entry, its function and evolution are critical to understanding zoonotic potential and pandemic risk. H7N2 is a subtype of avian influenza A virus. Its hemagglutinin (H7) binds preferentially to α-2,3-linked sialic acid receptors predominant in avian species, though certain strains exhibit dual receptor binding. H7N2 has caused outbreaks in poultry and sporadic, typically mild, infections in humans, highlighting its need for continuous surveillance.

• Structural Insights

The H7N2 HA trimer comprises a globular head domain (HA1), containing the receptor-binding site (RBS) and major antigenic sites, and a stem domain (HA2), which mediates membrane fusion. The cleavage of HA into HA1 and HA2 by host proteases is essential for viral infectivity. Structural studies reveal that antigenic drift in the HA1 head drives immune evasion, while the more conserved stem region is a target for broadly neutralizing antibodies.

Fig.1 Modelled three-dimensional structure of the H7 HA protein.¹

• Resistance and Signaling Pathways

While H7N2 strains are typically sensitive to neuraminidase inhibitors, monitoring for resistance mutations (e.g., in the NA gene) is vital. HA-mediated viral entry triggers host signaling pathways, including the PKC and MAPK pathways, to facilitate endocytosis. Subsequent viral replication can dysregulate host interferon (IFN) and NF-κB pathways, modulating immune responses and contributing to pathogenesis.

• Clinical Impact

Human infection with H7N2 can range from asymptomatic or mild conjunctivitis and upper respiratory symptoms to more severe lower respiratory tract complications, particularly in immunocompromised individuals. Its persistence in avian reservoirs poses a constant threat of adaptation for efficient human-to-human transmission.

• Antibodies Against H7N2 HA
  Neutralizing antibodies directed against H7N2 hemagglutinin are essential instruments for research and therapeutic advancements.
  • Accurately measure viral load and hemagglutinin expression in experimental models.
  • Trace antigenic evolution and epitope specificity associated with the H7 subtype.
  • Investigate mechanisms of viral entry and assess fusion inhibition.
  • Assess vaccine immunogenicity by quantifying neutralizing antibody titers.

Applications of Anti-H7N2 HA Neutralizing Antibodies

Fig.2 In vivo assessment of protective efficacy in murine models.²

• Therapeutic Candidate Screening and Development

Neutralizing monoclonal antibodies (mAbs) against H7N2 HA offer a direct therapeutic strategy. By blocking receptor binding or inhibiting the conformational changes required for membrane fusion, these antibodies can prevent viral entry into host cells. Our high-affinity anti-H7N2 HA mAbs serve as critical benchmarks for screening novel therapeutic candidates, assessing their neutralization potency, and guiding humanization efforts for clinical development.

• Serological Surveillance and Diagnostic Assay Development

Our antibodies are essential for developing sensitive and specific diagnostic assays. In ELISA or lateral flow formats, they enable the detection of H7N2 HA antigen in clinical or environmental samples for rapid outbreak identification. Furthermore, they are used in Hemagglutination Inhibition (HI) assays to measure strain-specific neutralizing antibodies in serum, crucial for serosurveillance studies and evaluating population immunity following vaccination or exposure.

• Vaccine Efficacy and Immunogenicity Research

Validated anti-H7N2 HA antibodies are vital for standardizing vaccine research. They are used in antigen-capture assays to quantify HA content in vaccine preparations. More importantly, as reference reagents in microneutralization assays, they help calibrate the measurement of neutralizing antibody responses elicited by candidate H7N2 vaccines, providing critical data on immunogenicity and potential cross-reactivity with other H7 subtypes.

Our Anti-H7N2 HA Specific Neutra™ Antibody Products

Creative Biolabs provides meticulously validated antibody solutions tailored for rigorous influenza research:

• Exceptional Specificity and Affinity: Our antibodies display minimal cross-reactivity with other influenza subtypes, ensuring precise detection and neutralization of H7N2.
• Thorough Validation Process: Each batch is validated for effectiveness in crucial applications, including Neutralization Assays, ELISA, Western Blot, and Immunofluorescence.
• Targeting Essential Epitopes: We provide antibodies that target both the variable head domain for strain-specific investigations and the conserved stem region for studies focusing on broad-spectrum therapeutics.
• Reliable and Reproducible Results: Produced under stringent quality control protocols to ensure consistency across batches, offering dependable, publication-ready results.

With an amount of expertise in antibody development and virology, Creative Biolabs is your trusted partner in pandemic preparedness research. We combine deep scientific knowledge with a commitment to providing high-performance, reliable research tools. Our H7N2 HA Specific Neutra™ Antibody Products are engineered to accelerate your path from basic virology to therapeutic discovery. Contact our team today to learn more and discuss your specific project requirements.

References

1. Sekine, Wataru, et al. "Adaptation of the H7N2 feline influenza virus to human respiratory cell culture." Viruses 14.5 (2022): 1091. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/v14051091
2. Ito, Mutsumi, et al. "Characterization of mouse monoclonal antibodies against the HA of A (H7N9) influenza virus." Viruses 11.2 (2019): 149. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/v11020149